Johnson & Johnson (JNJ) Minority Interest (2010 - 2023)
Johnson & Johnson (JNJ) posted Minority Interest of $1.3 billion for Q3 2023, up 113.56% sequentially from $590.0 million in Q1 2010.
Johnson & Johnson (JNJ) Minority Interest (2010 - 2023) Analysis & Trends
Johnson & Johnson has reported Minority Interest for 2 years, with the latest figure at $1.3 billion in Q3 2023.
- Quarterly Minority Interest changed N/A year-over-year to $1.3 billion in Q3 2023, while the trailing twelve-month figure through Jul 2023 was $1.3 billion (changed N/A YoY) and the FY2010 annual result came in at $590.0 million, changed N/A from the prior year.
- Minority Interest rose to $1.3 billion in Q3 2023 per JNJ's latest filing, from $590.0 million in the prior quarter.
- Over five years, Minority Interest peaked at $1.3 billion in Q3 2023 and troughed at $1.3 billion in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 2, 2023 | 1.26 Bn |
| Jan 3, 2010 | 590.00 Mn |